维普期刊资源整合服务平台（V6.5）

55篇 您的检索式：作者名="Stintzing S"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first - line treatment with cetuximab combined with either CAPIRI or CAPOX : An analysis of the German AIO KRK 0104 trial显示文摘	Modest DP Laubender RP Stintzing S	2013	Acta Oncologica2013，52，5：	1
2	Clinical relevance of EGFR and KRAS status in coloreetal cancer patients treated with monoclonal antibodies directed against the EGFR 显示文摘	Heinemann V Stintzing S Kirchner T	2009	Cancer Treat Rev2009，35，：	1
3	Early tumour shrinkage(ETS) and depth of response(DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) 显示文摘	Heinemann V Stintzing S Modestet DP	2015	Euro J of Cancer2015，，14：	1
4	Percutaneous radiofrequency ablation(RFA)or robotic radiosurgery(RRS)for salvage treatment of colorectal liver metastases显示文摘	Stintzing S Grothe A Hendrich S	2013	Acta Oncol2013，14，：	1
5	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized Ger- man AIO study KRK-0306 显示文摘	Stintzing S Neumann J Jung A	2011	J Clin Oncol2011，，：	1
6	Overexpre-ssion of MMP-9 and tissue factor in unstable carotid plaques associated with chlamydia pneumoniae, inflammation, and apoptosis显示文摘	Stintzing S Heuschmann P Barbera L	2005	Ann Vasc Surg2005，19，3：	1
7	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS:mutated tumours in the randomised German AIO study KRK-0306显示文摘	Stintzing S von Weikersthal L F Decker T	2012	Annals of oncology2012，23，7：	1
8	Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 : A randomized phase Ill study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment her wild - type KRAS( exon2 ) metastatic coloreetal cancer patients ( abstract ) 显示文摘	Stintzing S Jung A Rossius L	2013	ESMO European Cancer Congress2013，，：	1
9	Clinical relevance of EGFR and KRAS status in colorectal cancer pa- tients treated with monoclonal antibodies directed against the EGFR 显示文摘	Heinemann V Stintzing S Kirehner T	2009	Cancer Treatment Rev2009，35，：	1
10	Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer, results from the German AIO KRK-0104 trial显示文摘	Stintzing S Fischer von WL Vehling KU	2011	Br J Cancer2011，105，2：	1
11	Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis显示文摘	Stintzing S Heuschmann P Barbera L	2005	Ann Vasc Surg2005，19，3：	1
12	Differentiation patterning of vascular smooth muscle cells(VSMC) in ather- osclerosis显示文摘	Stintzing S Ocker M Hartner A	2009	Virchows Arch2009，455，2：	1
13	Impact of ethanolie lamiaceae extracts on herpesvirus infectivity in cell culture 显示文摘	REICHLING J NOLKEMPER S STINTZING F C	2008	Forschende Komplementarmedizin/Research in Complementary Medicine2008，15，6：	1
14	The expression pattern of PDX-1,SHH,Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer显示文摘	Quint K Stintzing S Alinger B		0，，：	1
15	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR 显示文摘	HeinemannV Stintzing S Kirehner T	2009	Cancer Treat Rev2009，35，3：	1
16	FOLFIRI plus eetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS:mutated tumours in the randomised German AIO study KRK-0306显示文摘	Stintzing S Fischer yon Weikersthal L Decker T et aI	2012	Ann Oncol2012，23，7：	1
17	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC):Analysis of patients with KRASmutated tumors in the randomized German AIO study KRK-0306显示文摘	Stintzing S Neumann J Jung A		Journal of Clinical Oncology0，，：	1
18	Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 triM: First- line therapy with FOLFIRI plus Cetuximab or Bevacizumab in patients with KRAS wild- type tumors in metastatic colorectal cancer显示文摘	Modest DP Stintzing S van Weikersthal LF	2015	J Clin Oncol2015，33，32：	1
19	Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial 显示文摘	Stintzing S Fischer yon WL Vehling KU	2011	Br J Cancer2011，105，2：	1
20	Prognostic value of ce- tuximab - related skin toxicity in metastatic colorectal cancer pa- tients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a random- ized trial of the GERMAN AIO CRC Study Group 显示文摘	Stintzing S Kapaun C Laubender RP	2013	International J Cancer2013，132，1：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示